VA-HILTON
24.1.2022 14:02:12 CET | Business Wire | Press release
Well-positioned to emerge from the pandemic stronger than ever, Hilton delivered a record year of development achievements. Already one of the world’s largest hotel companies, Hilton opened 414 properties, adding more than 67,100 rooms to its system, further emphasizing the scale, presence and leading brands of the company’s global portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220121005394/en/
“After a year of recovery and growth, it has been incredible to witness the resiliency of the travel industry and our team’s ability to embrace change while serving more guests in more hotels around the world,” said Chris Nassetta, President and CEO, Hilton. “We believe the desire to travel, experience new cultures and connect with others is core to the human experience. I can speak for all of us at Hilton when I say we’re looking forward to welcoming our guests and helping them make new memories in 2022.”
Global development efforts have continued to show strong performance through the pandemic. Hilton ended 2021 with more than 6,800 hotels across 18 brands in six continents, with robust net unit growth of 5.6%. The company’s development pipeline includes nearly 2,670 hotels representing approximately 408,000 rooms, nearly half of which are under construction.
“Hilton’s development continues to be a key performance indicator of how well-positioned we are for the long-term,” said Kevin Jacobs, CFO and president, global development, Hilton. “Hotel owners choose to work with us because of our premium commercial performance. With our capital light business model, we strive to maximize net unit growth, while continuing to deliver value for all our stakeholders.”
Celebrating A Year of Market and Category Milestones
- Historic Las Vegas Development: Hilton notably expanded its presence in the Las Vegas market, which is now home to 13 brands, including all three of our luxury brands, 36 hotels and more than 12,000 rooms. In June 2021, Hilton and Genting Group partnered in the historic opening of Resorts World Las Vegas , the largest multi-brand resort in Hilton’s history, integrating three premium brands – the largest Conrad Hotels & Resorts property in the world, one of the first LXR Hotels & Resorts locations in the U.S. and a marquee Hilton Hotels & Resorts hotel. Additionally, Curio Collection by Hilton re-emerged in Las Vegas with the introduction of Virgin Hotels Las Vegas, Curio Collection by Hilton .
- Significant All-Inclusive Expansion: Hilton’s all-inclusive portfolio expanded in 2021 with openings in the Caribbean and Latin America, including Hilton Cancun, an All-Inclusive Resort, Hilton Vallarta Riviera All-Inclusive Resort , Mangrove Beach Corendon Curaçao All-Inclusive Resort, Curio Collection by Hilton and The Yucatan Playa del Carmen All-Inclusive Resort, Tapestry Collection by Hilton .
- Hilton’s lifestyle brands gained momentum in Europe, the Middle East & Africa (EMEA) and Brazil. Canopy by Hilton made its debuts in France, UK and Spain. Motto by Hilton announced plans to open its first hotel in Europe with Motto Rotterdam Blaak in the Netherlands in 2022. Additionally, Brazil welcomed two Hilton brands with the debuts of Canopy by Hilton Sao Paulo Jardins and Almenat Hotel, Tapestry Collection by Hilton .
- Asia Pacific Growth: Hilton Nagasaki ’s flagship opening marked the company’s 500th hotel in Asia Pacific, while Hilton Lanzhou City Center ’s opening marked the 400th hotel in the Greater China and Mongolia region.
- Washington, D.C. Expansion: The company introduced its 25th hotel within the portfolio in Washington, D.C. with the debut of Hilton Washington DC Capitol Hill .
Recognizing Year of “Firsts” for the Brand Portfolios with Market Expansions
- Waldorf Astoria Hotels & Resorts expanded the brand’s West Coast presence with the opening of Waldorf Astoria Monarch Beach Resort & Club in Dana Pointe, California and signed a milestone management agreement with Orix Real Estate Corporation to expand the brand into Osaka, Japan in 2025.
- Management agreement was signed for the first Conrad Hotels & Resorts property in California with Conrad Los Angeles (opening Spring 2022) as well as the first in Tulum with Conrad Tulum Riviera Maya .
- LXR Hotels & Resorts was introduced in Africa and the Indian Ocean with Mango House Seychelles and in Asia Pacific with ROKU KYOTO, LXR Hotels & Resorts .
- Signia by Hilton debuted with the conversion and rebrand of Signia by Hilton Orlando Bonnet Creek . Additionally, Signia by Hilton Atlanta broke ground at Georgia World Congress Center.
- Curio Collection by Hilton surpassed 100 properties worldwide with the opening of Sable at Navy Pier Chicago, Curio Collection by Hilton .
- DoubleTree by Hilton extended its international reach to its 50th trading market with the opening of DoubleTree by Hilton Frankfurt Niederrad, the brand’s first in Germany.
- Tapestry Collection by Hilton introduced properties in Europe and the Chinese Mainland, including Atocha Hotel Madrid, Tapestry Collection by Hilton and Hollick Hotel Wen’an, Tapestry Collection by Hilton .
- Motto by Hilton announced plans to open its first hotels in Europe and Latin America in 2022 with Motto Rotterdam Blaak in the Netherlands and Motto Tulum in Mexico.
- Hilton Garden Inn entered into Australasia, South Korea, Thailand and Indonesia’s capital city Jakarta with Hilton Garden Inn Albany , Hilton Garden Inn Seoul Gangnam , Hilton Garden Inn Phuket Bang Tao and Hilton Garden Inn Jakarta Taman Palem , respectively. Additionally, the brand launched its large-scale franchise model in China , welcoming investors and independent owners to explore franchising opportunities.
- Hampton by Hilton celebrated milestones throughout the year, surpassing 2,700 open hotels and expanding into Ireland, Uzbekistan and Qatar, as well as the Cayman Islands with Hampton by Hilton Grand Cayman . Hampton also remains the fastest-growing international hotel brand in China, marking 200 open hotels, with an additional 600 signed development deals within the country. Additionally, starting 2022 strong, the brand was recognized for the 13th year in a row as the No. 1 hotel franchise by Entrepreneur ’s Franchise 500® , tying the record for most total No. 1 rankings in the Hotels & Motels category.
- Tru by Hilton opened its 200th hotel, adding nearly 100 hotels during the pandemic, and announced expansion into the Caribbean and Latin America, with developments in Brazil, Costa Rica, Dominican Republic, Mexico and Puerto Rico.
- Homewood Suites by Hilton unveiled a comprehensive brand refresh with a game-changing, all-new prototype – ‘Prototype 10.0’ – designed to offer added value and versatility for owners and developers, while exceeding the needs of guests who want the comforts of home.
- Home2 Suites by Hilton became one of the fastest-growing hotel brands as it reached 500 open properties in just 10 years and touts the largest pipeline in the U.S., with 437 properties in development. The brand also debuted in China , with the opening of the first of 1,000 Home2 Suites by Hilton properties in the region.
In addition to development milestones, Hilton continued to innovate to meet the evolving needs of travelers with the introduction of industry-leading programs and products, such as Confirmed Connecting Rooms by Hilton and Hilton Honors Digital Key Share , and the evolution of brand standards, including expanding its pet-friendly offerings . To learn more, visit newsroom.hilton.com .
About Hilton
Hilton (NYSE: HLT) is a leading global hospitality company with a portfolio of 18 world-class brands comprising more than 6,800 properties and more than 1 million rooms, in 122 countries and territories. Dedicated to fulfilling its founding vision to fill the earth with the light and warmth of hospitality, Hilton has welcomed more than 3 billion guests in its more than 100-year history, earned a top spot on the 2021 World’s Best Workplaces list and been recognized as a global leader on the Dow Jones Sustainability Indices for five consecutive years. In 2021, in addition to opening more than one hotel a day, Hilton introduced several industry-leading technology enhancements to improve the guest experience, including Digital Key Share, automated complimentary room upgrades and the ability to book confirmed connecting rooms. Through the award-winning guest loyalty program Hilton Honors, the nearly 128 million members who book directly with Hilton can earn Points for hotel stays and experiences money can’t buy. With the free Hilton Honors app , guests can book their stay, select their room, check in, unlock their door with a Digital Key and check out, all from their smartphone. Visit newsroom.hilton.com for more information, and connect with Hilton on Facebook , Twitter , LinkedIn , Instagram and YouTube .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005394/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
